TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23330658
Drug: Candesartan 4
Normalized name: candesartan 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 4 mg/day
Study: 23330658
Drug: Amlodipine 2.5
Normalized name: amlodipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 2.5 mg/day
Study: 16050407
Drug: Blockers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blockers of the renin-angiotensin system (RAS)
Study: 16050407
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of RAS blockers in presence of microalbuminuria
Study: 12853792
Drug: 180 mmol
Normalized name: PEG-180
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mmol (3%) ALA administered for 6 hours
Study: 12853792
Drug: 8 mmol
Normalized name: potassium 8 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mmol (0.2%) HAL administered for 4 hours
Study: 12853792
Drug: 8 mmol
Normalized name: potassium 8 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mmol HAL administered for 2 hours followed by 2 hours of resting time (2+2 hours concept)
Study: 12853792
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of HAL
Study: 12853792
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of ALA or HAL
Study: 2696390
Drug: Classical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical therapy consisting of isoniazid and rifampicin for a nine-month period.
Study: 29722425
Drug: Indocyanine green-based
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green-based photodynamic therapy
Study: 29722425
Drug: Indocyanine green-based
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green-based photodynamic therapy with 805-nm diode laser
Study: 29722425
Drug: Indocyanine green-based
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green-based photodynamic therapy with 830-nm light-emitting diode
Study: 29722425
Drug: Methyl aminolevulinate-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl aminolevulinate-based photodynamic therapy
Study: 18566974
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral doses of KW-6002 greater than 5 mg
Study: 18566974
Drug: MRS 1745
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRS 1745 (A(2B) receptor selective antagonist)
Study: 16227335
Drug: i.m. tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. tramadol 100 mg
Study: 11862087
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 100 mg orally, three times daily
Study: 11862087
Drug: Topical steroid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid, topical antibiotic, and artificial tears
Study: 10549464
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: propofol 2 mg kg‐1 and remifentanil 2 micrograms kg‐1
Study: 10549464
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: propofol 2 mg kg‐1, remifentanil 1 microgram kg‐1 and lignocaine 1 mg kg‐1
Study: 7606988
Drug: Salmeterol, 50
Normalized name: Fluticasone-Salmeterol, 500 mcg-50 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol, 50 micrograms twice a day
Study: 7606988
Drug: Albuterol, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol, 400 micrograms four times a day
Study: 31234865
Drug: Single low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single low-dose primaquine added to artemether-lumefantrine treatment
Study: 31234865
Drug: Artemether-lumefantrine treatment
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine treatment without primaquine
Study: 28070970
Drug: Baby lotion
Normalized name: Baby Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baby lotion (L)
Study: 23126384
Drug: montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: montelukast (5 or 10 mg, once daily)
Study: 23126384
Drug: salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: salmeterol (50 μg, b.i.d.)
Study: 16426100
Drug: Modafinil (340
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (340 mg, N = 44; 425 mg, N = 82)
Study: 14503435
Drug: Constraint-Induced Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-Induced Therapy (CI therapy)
Study: 8724448
Drug: Scopolamine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.1 mg, 0.25 mg, 0.5 mg)
Study: 1314536
Drug: Live-attenuated vaccine
Normalized name: Chikungunya vaccine (live, attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live-attenuated vaccine (28,000 pfu, 2800 pfu, or 280 pfu of Oka/Merck strain virus)
Study: 1314536
Drug: Heat-inactivated vaccine
Normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-inactivated vaccine (comparable antigen content to live vaccine)
Study: 1314536
Drug: High-dose groups
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose groups (greater than or equal to 7.1 antigen units)
Study: 1314536
Drug: Lowest dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest dose (less than or equal to 0.71 antigen units)
Study: 2864890
Drug: Procaterol hydrochloride
Normalized name: procaterol hydrochloride
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol hydrochloride tablet formulation
Study: 2864890
Drug: Procaterol hydrochloride
Normalized name: procaterol hydrochloride
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol hydrochloride syrup formulation
Study: 26311100
Drug: Intra-articular dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular dexmedetomidine (2 μg/kg body weight) and ropivacaine (18 mL)
Study: 26311100
Drug: Intra-articular dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular dexmedetomidine (1 μg/kg body weight) and ropivacaine (18 mL)
Study: 26311100
Drug: Intra-articular ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular ropivacaine (20 mL)
Study: 23567483
Drug: 0.1 μg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 μg/kg/min remifentanil infusion (Group R1)
Study: 23567483
Drug: 0.2 μg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 μg/kg/min remifentanil infusion (Group R2)
Study: 18454862
Drug: Walnut supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut supplement (75 g/d)
Study: 16567267
Drug: High-dose thiamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose thiamine (250 mg/day) and pyridoxine (200 mg/day)
Study: 3189208
Drug: Vitamin-mineral supplements
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-mineral supplements
Study: 31664766
Drug: BOS161721 (1-240
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOS161721 (1-240 mg, intravenous and subcutaneous doses)
Study: 31664766
Drug: BOS161721 (subcutaneous)
Normalized name: Immunoglobulin g1 (251-tyrosine,253-threonine,255-glutamic acid), anti-(human interleukin 21) (human-mus musculus monoclonal bos161721 .gamma.1-chain), disulfide with human-mus musculus monoclonal bos161721 .kappa.-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOS161721 (subcutaneous)
Study: 16970214
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg/d) added to ongoing statin therapy for 6 weeks
Study: 16970214
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to ongoing statin therapy for 6 weeks
Study: 11385384
Drug: Acetylcholine (10(‐8),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholine (10(‐8), 10(‐7), 10(‐6), and 10(‐5) mol/L)
Study: 30094437
Drug: Oat protein
Normalized name: Potassium Olivoyl Hydrolyzed Oat Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat protein (25 g protein) for 19 days
Study: 24920942
Drug: Coload (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coload (15 ml/kg of crystalloid after intrathecal injection)
Study: 24920942
Drug: Preload (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preload (15 ml/kg of crystalloid before intrathecal injection)
Study: 22419728
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg iv zoledronate
Study: 14517524
Drug: Chlorpheniramine maleate
Normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine maleate (0.35 mg/kg/d) and/or prednisolone (2 mg/kg/day)
Study: 9504181
Drug: NaF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaF treatment (0.02%, 0.05% or 0.1%)
Study: 2878675
Drug: Nifedipine (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (in patients pretreated with a beta blocker)
Study: 31698917
Drug: Adipose-derived stromal
Normalized name: Autologous adipose-derived stromal vascular fraction cells
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose-derived stromal cell (ASC) therapy
Study: 28453471
Drug: ELND005 (scyllo-Inositol)
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ELND005 (scyllo-Inositol) 250 mg twice daily (BID)
Study: 28453471
Drug: ELND005 (scyllo-Inositol)
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ELND005 (scyllo-Inositol) 250 mg once daily (QD)
Study: 21045172
Drug: Whey (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey (0.3 g/kg lean body mass)
Study: 21045172
Drug: Casein (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein (0.3 g/kg lean body mass)
Study: 19681415
Drug: Ketamine pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine pre-treatment (10 mg in 1.0 ml saline) under tourniquet for 30 seconds before propofol injection.
Study: 19681415
Drug: Ketamine added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine added to propofol (10 mg in 9 ml propofol mixed with 1.0 ml saline).
Study: 16696744
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 mug daily self-injection for a median of 19 months, with daily oral supplements of 1,000 mg calcium and 400 to 1,200 IU vitamin D.
Study: 9777817
Drug: Incorrect treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incorrect treatment for renin profile but correct for age-race subgroup
Study: 7889894
Drug: K‐85 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: K‐85 2 g twice daily
Study: 7889894
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil 2 g twice daily (placebo)
Study: 30453950
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri V3401 (5 × 10^9 CFU daily)
Study: 28157261
Drug: MG-assisted TSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG-assisted TSP
Study: 21273603
Drug: CCND1 rs9344
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCND1 rs9344 genotype (G allele carriers: GG or AG)
Study: 16968574
Drug: Trazodone prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone prolonged-release 150-450 mg/day (n = 62)
Study: 16968574
Drug: Sertraline 50-100
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50-100 mg/day (n = 60)
Study: 15351368
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MEP and SEP
Study: 11049800
Drug: Oral miltefosine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral miltefosine, 50 mg given twice daily for 14 days (group A)
Study: 11049800
Drug: Oral miltefosine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral miltefosine, 50 mg given twice daily for 21 days (group B)
Study: 11049800
Drug: Oral miltefosine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral miltefosine, 50 mg given twice daily for 28 days (group C)
Study: 7618720
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of bupivacaine
Study: 7618720
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of bupivacaine plus 10 micrograms of sufentanil
Study: 7618720
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of bupivacaine and 10 micrograms of sufentanil
Study: 2144206
Drug: Zoladex depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex depot supplemented by flutamide 250 mg 3 qid
Study: 318577
Drug: Liquid antacid
Normalized name: GNP Liquid Antacid Maximum Strength 400mg-400mg-40mg/5ml Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid antacid
Study: 22038523
Drug: Rosiglitazone 4‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4‐8 mg/day
Study: 22038523
Drug: Pioglitazone 30‐45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30‐45 mg/day
Study: 20308972
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of arginine ingested in a single dose 60 minutes prior to exercise
Study: 16291760
Drug: Synthetic protein
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic protein N (10, 30, or 100 microg/dose)
Study: 16291760
Drug: Synthetic protein
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic protein R (10, 30, or 100 microg/dose)
Study: 16291760
Drug: Synthetic protein
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic protein C (10, 30, or 100 microg/dose)
Study: 9479340
Drug: CytoRich liquid-based
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: CytoRich liquid-based preparation (AutoCyte, Inc.)
Study: 8558939
Drug: Allopurinol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (100 mg/m2 orally)
Study: 8558939
Drug: Allopurinol (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (one dose)
Study: 8558939
Drug: Allopurinol (concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (concomitant with methotrexate therapy)
Study: 8558939
Drug: Methotrexate therapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate therapy only
Study: 6184574
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg nitrendipine
Study: 28877748
Drug: GSK2586881 (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2586881 (0.4 mg/kg) administered twice daily for 3 days
Study: 17129383
Drug: Paclitaxel at
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel at a dose of 175, 210, or 250 mg/m2
Study: 11401123
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg daily for 12 weeks
Study: 6695162
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting beta blocker (oxprenolol R 160 mg)
Study: 30807294
Drug: Modified dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified dual therapy
Study: 20190028
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 2 x 600 mg/daily for 8 weeks
Study: 15823451
Drug: Shortened version
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shortened version of the ACQ (symptoms plus short‐acting beta2‐agonist)
Study: 12753323
Drug: Steroid withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid withdrawal using Simulect (IL-2 receptor inhibitor)
Study: 10839763
Drug: Azithromycin 600
Normalized name: azithromycin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 600 mg orally once a week for 1 year
Study: 2860043
Drug: Steroids or
Normalized name: Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids or a combination with prednisolone and sulfasalazine
Study: 29898870
Drug: Vaccine regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine regimen (intramuscular injection of ALVAC-HIV vector [vCP2438] at 0, 1, 3, 6, and 12 months plus bivalent subtype C gp120 and MF59 adjuvant at 3, 6, and 12 months)
Study: 29898870
Drug: Vaccine regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine regimen
Study: 17698218
Drug: tirofiban infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: tirofiban infusion and sirolimus-eluting stents (SES)
Study: 17698218
Drug: tirofiban infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: tirofiban infusion and SES
Study: 1451242
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (1.5 M units) administered over 30 minutes
Study: 22527648
Drug: Repeated interventional
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated interventional treatment (average 10 times, approximately 107 single injections during each treatment cycle)
Study: 20855664
Drug: Baseline GDF-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline GDF-15 levels (per 100 ng/L)
Study: 18030865
Drug: Visual medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual medication schedule with brief counseling
Study: 7588454
Drug: Felbamate (FBM)
Normalized name: Felbamate
DrugBank: Felbamate (DB00949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felbamate (FBM) monotherapy
Study: 28838862
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg per day)
Study: 25452452
Drug: Nivolumab 2
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 2 mg/kg
Study: 25452452
Drug: Nivolumab 10
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 10 mg/kg
Study: 19119079
Drug: Routine hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine hospital based 6‐monthly clinical review
Study: 14587108
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis during laparoscopic cholecystectomy
Study: 10877008
Drug: Effervescent paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent paracetamol tablets (2 x 500 mg Pinex Brusetablett, Alpharma AS)
Study: 10877008
Drug: Ordinary paracetamol
Normalized name: ordinary salt combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary paracetamol tablets (2 x 500 mg Panodil tablets, SmithKline Beecham)
Study: 10877008
Drug: Effervescent paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent paracetamol tablets
Study: 10877008
Drug: Ordinary paracetamol
Normalized name: ordinary salt combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary paracetamol tablets
Study: 9408153
Drug: Doxorubicin-containing chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-containing chemotherapy with involved field radiotherapy (n = 58)
Study: 9408153
Drug: Doxorubicin-containing chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-containing chemotherapy without involved field radiotherapy (n = 18)
Study: 8458821
Drug: Antioxidant vitamin
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamin mixture (daily doses of 592 mg of alpha‐tocopherol equivalents, 1,000 mg of ascorbic acid, and 30 mg of beta‐carotene)
Study: 29444414
Drug: Caffeine (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (4.8 ± 0.4 mg/kg body mass)
Study: 23225450
Drug: Temsirolimus and
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus and bevacizumab combination (arm A)
Study: 8198025
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg twice daily, starting 2 weeks before PTCA and continuing after successful PTCA until follow-up angiography at 26 +/- 2 weeks.
Study: 10075142
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg twice daily
Study: 3147048
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose theophylline (5-10 mg/l)
Study: 3147048
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose theophylline (10-15 mg/l)
Study: 3147048
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose theophylline (15-20 mg/l)
Study: 27350068
Drug: Tabalumab 100
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab 100 mg + Dexamethasone 20 mg/day + Bortezomib 1.3 mg/m² (Cohort 1)
Study: 27350068
Drug: Tabalumab 300
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab 300 mg + Dexamethasone 20 mg/day + Bortezomib 1.3 mg/m² (Cohort 2)
Study: 27350068
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Tabalumab 100 mg or 300 mg + Dexamethasone + Bortezomib)
Study: 26276751
Drug: Soy bread
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy bread (34 mg isoflavones/slice)
Study: 22976766
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) with imiglucerase
Study: 12800782
Drug: Nasal CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal CPAP treatment
Study: 12800782
Drug: Placebo-controlled treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-controlled treatment trials